The Expression Study Of Survivin Related Factors In Xinjiang Kazak's Esophageal Cancer

Objective:To investigate the expressions of c-IAP2 Bcl-2 STAT3 cyclinD1 PTEN and VEGF correlated with apoptosis adjustment gene Survivin in Kazak's esophageal carcinoma tissues and its adjacent non-carcinoma tissues and to find relationships between Survivin and these six genes. Methods: RT-PCR was used to detect the expressions of these six genes in carcinoma tissues and its adjacent non-carcinoma tissues in 32 Kazak esophageal cases, Western-bolt performed to evaluate the levels of proteins. Results: In Xinjiang Kazak's esophageal cancer(1)The positive expression rates of these six genes in 32 cases were over 50.0%, the c-IAP2 was 93.75%, cyclinD1 was 87.5%,VEGF was 84.38%. The expression levels of c-IAP2 STAT3 PTEN and VEGF were significantly increased in carcinoma tissues compared to the adjacent non-carcinoma ones(P<0.05). There were difference in the expressions of c-IAP2 STAT3 PTEN VEGF between carcinoma tissues and its adjacent non-carcinoma tissues (P<0.05). (2)PTEN protein has the low expression status and VEGF has the high expression status in carcinoma tissues. (3)There were expression correlationship between Survivin and c-IAP2 STAT3 PTEN VEGF in carcinoma tissues (P<0.05). (4)We found that the expression of cyclinD1 has a correlationship with c-IAP2 Bcl-2 PTEN; that the expression of PTEN has a correlation with c-IAP2 STAT3 cyclinD1 VEGF (P<0.05). (5)The statistic data show that the expression of cyclinD1 correlated with differentiated degree stages; the expressions of Bcl-2, STAT3 correlated with lymph node metastasis; the expression of VEGF correlated with sex, lymph node metastasis (P<0.05). Conclusion: Survivin plays an important role in promote carcinogenesis and development of Kazak's esophageal cancer, though regulating apoptosis, cell cycle and vessel genesis. These six genes could be identified as molecular markers for prediction early diagnosis, and clinical prognosis in Xinjiang Kazak's esophageal cancer.